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Highlights  
 Increased TG2 expression in CF epithelia increases TGFβ1 levels. 
 Increased TGFβ1 and TG2 leads to Epithelial Mesenchymal Transition (EMT). 
 EMT leads to poor CFTR stability and increased matrix deposition 
 Selective Inhibition of TG2 helps restore CFTR stability and leads to reversal of 
EMT. 
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Abstract 
Cystic fibrosis (CF) is a genetic disorder caused by mutation of the cystic fibrosis 
transmembrane conductance regulator (CFTR) for which there is no overall effective 
treatment. Recent work indicates Tissue Transglutaminase (TG2) plays a pivotal 
intracellular role in proteostasis in CF epithelia and that the pan TG inhibitor cysteamine 
improves CFTR stability. Here we show TG2 has another role in CF pathology linked 
with TGFβ1 activation and signalling, induction of Epithelial-Mesenchymal Transition 
(EMT), CFTR stability and induction of matrix deposition. We show that increased TG2 
expression in normal and CF bronchial epithelial cells increases TGFβ1 levels, promoting 
EMT progression, and impairs tight junctions as measured by Trans Epithelial Electric 
Resistance (TEER) which can be reversed by selective inhibition of TG2 with an 
observed increase in CFTR stability. Our data indicate that selective inhibition of TG2 
provides a potential therapeutic avenue for reducing fibrosis and increasing CFTR 
stability in CF. 
Key words 
Tissue transglutaminase, Cystic fibrosis, Transforming Growth Factor β, Epithelial-
Mesenchymal Transition, cystic fibrosis transmembrane conductance regulator. 
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1. Introduction  
Cystic fibrosis (CF) is a genetic disorder caused by mutation of the cystic fibrosis 
transmembrane conductance regulator (CFTR) [1]. Of the 1900 mutations now 
recognised to be present in CFTR the most common is F508del, all of which lead to the 
abnormal transport of chloride and sodium across the epithelium, resulting in multiple 
clinical manifestations of which lung disease characterised by chronic lung obstruction, 
infection and inflammation is the major cause of morbidity. CF affects not only the lungs, 
but also the pancreas, liver and intestines. True to its terminology fibrosis of the pancreas 
was noted when the disease was first recognised and uncontrolled airway remodelling is 
now recognised to start early in life and is linked to a poor pulmonary outcome with 
extensive fibrosis [2]. Transforming growth factor β1 (TGFβ1) is a key growth factors 
involved in fibrosis, including cystic fibrosis where increased levels are reported in lungs 
[3]. In addition to its pro-inflammatory properties TGFβ1 has been shown recently to 
inhibit the biosynthesis of CFTR and also prevents the biofunctional rescue of CFTR, 
especially the F508del [4]. Importantly over-expression of TGFβ1 in the CF lung has 
been associated with a more severe CF phenotype.  
Current treatment for CF is limited and largely confined to the relief of patient symptoms. 
This includes use of anti-inflammatory agents and antibiotics to suppress microbial 
infection. Lung transplantation may be necessary as the condition progresses, but both 
lungs need to be, replaced to prevent infection. Recently, new therapeutic avenues have 
been applied to CF treatment, such as the use of CFTR correctors and potentiators to 
improve the cell processing and function of the mutant CFTR [5]. For example some 
small compounds can correct the function of F508del-CFTR in CF cells by improving its 
folding in the ER and stabilizing the protein during its secretion to the cell surface. 
Importantly in cell models, the effect of the compounds can be detected within 3 hours. 
However, one recent corrector that reached a clinical trial, VX-809, failed to rescue the 
functional defect of F508del-CFTR in nasal epithelium and did not improve lung function 
in patients. Recently, another family of compounds named CFTR potentiators, especially 
VX-770, have been shown to improve CFTR function in cell models [6]. By increasing 
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the open time of CFTR, VX-770 reduces Na
+
 and fluid absorption and therefore prevents 
the dehydration of the apical surface. 
In other studies the application of the pan inhibitor cysteamine has been used in cell and 
animal models and more recently in early phase clinical trials. When used together with 
epigallocatechin gallate (EGCG, a green tea flavonoid that inhibits the enzyme Casein 
Kinase 2), improved and sustained mutant CFTR function was reported in patient nasal 
epithelial cells and in sweat ducts [7]. However, cysteamine, in addition to its action as a 
pan but relatively poor inhibitor of transglutaminases, is also an inhibitor of cysteine 
proteases and has been reported to have a diverse range of other potential targets. Its 
ability to inhibit cysteine proteases may also be important in preventing CFTR 
degradation in CF and in the prevention of apoptosis but these actions remain to be 
proven. The other target of cysteamine    Tissue Transglutaminase (TG2) is reported to 
play a pivotal role in proteostasis in CF epithelia
 
demonstrating an intracellular 
involvement of this multifunctional enzyme in CF [7]. This work proposed that in CF the 
dysfunctional CFTR induces a reactive oxygen species response which in turn triggers 
activation of intracellular TG2 leading to protein crosslinking, culminating in blocked 
autophagy and protein aggregate accumulation. The work also indicated that in the CF 
inflammatory response, intracellular crosslinking by TG2 inhibited the anti-inflammatory 
peroxisome proliferator-activated receptor γ (PPARγ), leading to sustained activation 
of the inflammatory process. Importantly use of the pan transglutaminase inhibitor 
cysteamine can reverse these observations [7]. 
In addition to this intracellular role TG2 is also reported to have a number of extracellular 
functions which generally manifest themselves in a variety of human diseases. Increases 
in TG2 expression are normally associated with injury or stress resulting in its secretion  
onto the cell surface and into the extracellular matrix (ECM) through a non-conventional 
mechanism involving cell surface heparan sulphates [8]. In the ECM Ca
2+ 
levels are high 
resulting in displacement of intarcellular regulator GTP, leading to the activation of TG2 
where it can contribute to other important CF pathologies. For example, as referred to 
earlier, during childhood, CF lungs and other tissues like the pancreas, intestine and liver 
develop fibrosis resulting in the remodelling and dysfunction of these organs as the 
disease progresses for which there is presently no therapy. Extracellular TG2 is known to 
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be a key player in the development of tissue fibrosis via its ability to crosslink matrix 
proteins leading to their increased deposition and stability and via its ability to activate 
matrix bound TGFβ1 [9]. Recent work also suggests that TG2 mediated crosslinking of 
TGFβ into the matrix may prolong the activity of TGFβ [10]. Moreover, expression of 
TG2 can be upregulated by TGFβ1 thus, propagating the fibrotic effects of TG2 and 
increased levels of TGFβ1 are found in the CF lung [11].       
TG2 is also reported to be involved in epithelial-mesenchymal transition (EMT) [12]. A 
process thought to be important in a number of fibrotic conditions [13]. Over-expressed 
in highly invasive cancers, TG2 mediates EMT via its ability to enhance the activation of  
NF-κB, TGFβ1 and TNFα [12].   
In this paper we have explored the role of TG2 in CF pathology in particular its link with 
TGFβ1 activation and signalling, induction of EMT, CFTR stability and the induction of 
fibrosis. We show that the presence of TG2 in both normal and CF bronchial epithelial 
cells promotes EMT progression leading to increased motility and increased fibronectin 
(FN) expression and deposition, via a TGFβ1-stimulated pathway involving TG2 
mediated matrix bound TGFβ1. We will also show that selective inhibition of TG2 
reduces TGFβ1 levels and leads to reversal of this process which is accompanied by an 
increase in the stability and improvement in CFTR processing in CF airway bronchial 
epithelial cells. 
2. Material and methods 
2.1 Cell Culture 
IB3-1 cells (a mutant tracheal epithelial cell line with a heterozygote mutation, 
F508del/W1282X, leading to the loss of CFTR channel function and immortalized by 
SV-40 transfection) and C38 cells (“add back” IB3-1 cell line which has a truncated 
CFTR channel with 119 residues missing but functional with elevated basal Cl- ion 
efflux) were obtained from Johns Hopkins University (Baltimore, USA). HBEC (primary 
Human Bronchial Epithelial cell, isolated from surface epithelium of human bronchi) was 
a kind gift from Dr Lindsay Marshall (Aston University, UK). Cells were cultivated in 
Airway Epithelial cell Medium (AEM) containing bovine pituitary extract, epidermal 
growth factor, insulin, hydrocortisone, epinephrine, triiodo-L thyronine, transferrin and 
retinoic acid (Promocell, UK). 
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2.2 ALI culture 
Transwell® inserts with a surface area of 0.33cm
2
 and 0.4μm pore size were inserted into 
Transwell® companion plates. 100μg/ml solution of Collagen IV in 3% (v/v) acetic acid 
was added to each insert membrane and allowed to attach for 45min at room temperature. 
Media was then used to rinse inserts to neutralize the acidity of the solution. 3×10
4
 cells / 
300μl of AEM media was added to each insert and 600μl of complete media added to the 
well underneath each insert. The cells were cultured for 4 days. On the 3
rd
 day, TG2 
inhibitors or the TGFβ receptor inhibitor was added and cells incubated for a further 12 h, 
after which media was removed and the cells then exposed to air. Media in companion 
Transwell® plates was replaced and the inhibitor introduced. Cells were then cultured for 
14 days during which basal medium with or without inhibitor was changed on alternate 
days. When cells cultured in ALI condition were transfected with TG2 shRNA or TG2 
virus all transfections /transductions were undertaken prior to ALI culture. 
2.3 Treatment of cell with Inhibitors. 
All TG2 inhibitors used in this study were synthesized in the Aston laboratories. R283 is 
a specific TG inhibitor not selective for TG2 but shown to penetrate cells [14]. R292, 
R294 and R281 are peptidic water soluble inhibitors that are cell impermeable [15] and 
able to differentiate between TG2 and Factor XIIIa. 1-155, 1-33, 2-18 and 1-159 are 
peptidomimetic inhibitors that are highly selective for TG2 [16, 17]. 1-155 is cell 
permeable and 1-159 is cell impermeable [17]. R283 is used at 500µM, 1-155 is used at 
1µM or 5µM, 1-33 is used at 50µM, 1-159 at 5 or 10µM, R294 is used at 500µM, 2-18 is 
used at 50µM, R281 and R292 is used at 250µM. Cells were treated for 48h with an 
inhibitor unless otherwise stated. At the time this work was undertaken, the inactivating 
antibody against TG2 that we have used previously [14] was not readily available due to 
its pharmaceutical development. 
For inhibition of TGFβ signalling the TGFβ receptor inhibitor SB 431542 (Sigma-
Aldrich, UK) was used at concentration of 10µM, which by the XTT assay was shown to 
be non-toxic to the cells. 
2.4 Inhibition of TG2 with TG2 shRNA 
5×10
5
 cells were seeded into 6-well plates in 2ml of medium. The cells were incubated 
overnight. 10nM of TG2 shRNA (CACAAGGGCGAACCACCTGAA) was mixed with 
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12μl of Lipofectamine 2000 Transfection reagent and were used according to 
manufacturer instructions. The plates were gently swirled around, incubated for 24h at 
37
o
C, 5% CO2 and used thereafter. The virus containing empty vectors were used as the 
control transduction treatment. 
2.5 Overexpression of TG2 
The procedure used is that reported in Wang et al [14]. 5×10
5
 cells were sub-cultured on 
6-well plates in complete media and cultured overnight. An aliquot of Lentiviral particles 
carrying TG2 or the TG2 mutant of interest was added to the wells and cells were 
incubated at 37
o
C for 48h with two more re-infections carried out every 24h. The virus 
containing empty vectors were used as the control transduction treatment. 
2.6 Cell migration assay 
The experiment was performed using the ESSEN IncuCyte system. Graduated 96-well 
plates from ESSEN were pre-coated with FN and used to seed IB3 and C38 cells in the 
presence or absence of TG2 inhibitor R283. Once reaching 90-95% confluency, a wound 
was introduced on each well using Wound maker 96 instrument (ESSEN instruments). 
Cells were allowed to migrate at 37°C for 24 h. Cell migration was monitored and 
analysed by the IncuCyte software. The mean ± S.D. from 3 separate experiments was 
calculated and plotted using the ESSEN IncuCyte software. 
2.7 Western Blotting 
The cells with or without the treatments were lysed in cell lysis buffer (containing 5mM 
DTT, 150mM NaCl, 1mM EGTA, 1mM PMSF, 1%(V/V) protease  inhibitor cocktail, 
1mM Sodium orthovanadate in 50mM Tris-Cl, pH 7.4 [18]). Following pre-clearing the 
samples at 300×g for 5min. The proteins were separated via SDS-PAGE and the presence 
of the target proteins were detected via Western blotting using specific antibodies as 
described previously [18]. GAPDH was used as the equal loading control.  
2.8 Transglutaminase activity assay  
The transglutaminase activity in the cell lysates or on the cell surface was performed as 
described previously [8, 18]. Briefly, 96-well plates were coated with 50μl of a 5μg/ml 
FN overnight, 50μg protein in the whole cell lysates (WCL) was incubated on the FN 
coated plates in the presence of 10mM calcium, 1mM DTT, 0.1mM biotin-cadeverine 
(BCD) in a final volume of 100μl/well of 50mM Tris-Cl, pH 7.4. The plate was then 
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incubated at 37
o
C for 2h. Following 3 washes with 50mM Tris-HCl, pH 7.4.  the wells 
were blocked with heat inactivated 3% (w/v) Bovine Serum Albumin, BSA, in 50mM 
Tris-Cl, pH 7.4 (blocking buffer) for 30 min at 37
oC and then incubated with 100μl of 
peroxidise-conjugate of Extr-avidin (1:1,000 dilution) for 1h at 37
o
C. After another 3 set 
of washes, transglutaminase activity was measured using SigmaFast® OPD and the 
reaction was stopped by 3N HCl. Absorbance was detected at 490nm using a plate reader 
[8].  
For cell surface transglutaminase activity, 2×10
4
 cells/well in serum-free medium were 
seeded onto FN pre-coated 96-well plates in the presence of 0.1 mM biotin-cadaverin and 
incubated at 37
o
C for 2h. After removal of media the reaction was stopped by washing 
wells with 2mM EDTA in PBS, pH 7.4. 100μl of 0.1% (w/v) sodium deoxycholate in 
2mM EDTA in PBS, pH 7.4, was then added to each well and incubated on a slow shaker 
for 10 min at room temperature. The transglutaminase activity was measured using Extr-
avidin substrate as described above.  
2.9 Immunofluorescence staining in submerged cell culture 
Cells in submerged or ALI cultures with the treatments required were washed three 
washes with PBS, pH 7.4, the cells were fixed with 3.7 % (v/v) paraformaldehyde in 
PBS, pH 7.4 and permeabilized with 0.1% Triton in PBS, pH 7.4. Following blocking 
with 3% BSA in PBS, pH 7.4 (the blocking buffer) at 37°C for 30 min, the cells were 
incubated with primary antibody and fluorescence-conjugated secondary antibody at 
37
o
C for 2h, respectively.  The cells were mounted in mounting medium containing 4’, 6 
-diamidino-2-phenylindole (DAPI). The fluorescence signals were detected using a 
Leica® SP5 confocal microscope. 
2.10 Cell fractionation 
IB3 cells were treated with TG2 inhibitors for 48h with media changed every 24h.  
Subcellular fraction were realized by using the “Subcellular Fractionation Kit for 
Cultured Cells” (Thermo Scientific, UK). Briefly, at each step, cells were lysed with a 
specific lysis buffer and a centrifugation undertaken according to the manufacturer’s 
instructions to isolate each subcellular fraction. Western blotting was performed to detect 
the target proteins. 
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For the ECM fractions of the cells, IB3 cells were seeded into 60mm Petri dishes in the 
presence or absence of TG2 inhibitor R283 or 1-155, while addition of 1µg/ml rhTG2 
was used as the control treatment. The cells were cultured for 48 h and lifted from the 
ECM using 2mM EDTA in PBS, pH 7.4. The remaining ECM was collected into 
Laemmli buffer and Western blotting was performed to detect the presence of TGFβ1 in 
the ECM.  
2.11 Trans-Epithelial Electrical Resistance (TEER) 
The TEER values were measured using Epithelial voltohmmeter (World Precision 
Instrument) according to the manufacturer’s instructions. The final values were expressed 
as Ω × cm2. The transepithelial electrical resistance values obtained in the absence of 
cells and the presence of collagen coating membrane were considered as background 
measurements, which were subtracted from the TEER values from the experimental 
groups. To measure TEER using electrodes media was added to the surface of cells in 
inserts carefully. The electrodes attached to the voltohmmeter were then inserted into 
each insert with the longer arm extending into the well and the shorter arm into the insert 
above the cells. Caution was taken not to disturb cells. The measurement was done 
passing AC current through the cells consequently, taking the resistance as the current 
passes through in ohms. This was done in triplicate with electrodes dipped intermittently 
in 70% (v/v) Industrial Methylated Spirit (IMS) before each use. 
2.12 Total TGFβ Assay via ELISA 
ELISA was performed to detect the presence of TGFβ1 as described previously [20]. 
Briefly, 2.5 × 10
5
 cells were cultured on 6 well plates and allowed to settle down for 2 
hours, followed by incubation with serum free medium containing supplements in the 
presence or absence of TG2 inhibitors. The presence of TGFβ1 was measured following 
the manufacture’s instruction (eBiosciences).  The 300µl of media was collected from 
cell cultures and centrufuged at 300×g for 5 minutes. The supernatant was then decanted 
and assayed for TGFβ1.  
2.13 Reverse Transcription- Polymerase Chain Reaction (PCR) 
RNA was extracted from the cells using TRIzol
®
 followed by alcohol precipitation. 
Reverse-transcription was performed using the Qiagen Sensiscript
®
 Reverse transcriptase 
Kit, RNA fragments were transribed into cDNA. Briefly, 50ng of RNA template for each 
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cell line was added to the master mix containing 10x buffer mix, 5mM of dNTP mix 
containing 5mM of each nucleotide, 10uM Oligo-dT primer, Sensicript Reverse 
Transcriptase
(R)
 and RNAse free water to make up volume. The mix was vortexed 
carefully and incubated at 37
o
C for 60minutes. This mix containing the cDNA was then 
used for PCR. 
2.14 Real Time- RT-PCR 
Real time-PCR was performed according to the default conditions on the Stratagene
®
 
MX-3000P real-time PCR machine of which the annealing temperature was updated to 
accommodate the primers used for the real time-PCR. Real time-PCR was performed 
according to manufacturer’s protocol of the Qiagen Quantitect SYBR Green® PCR kit. 
Primers for TGFβ1 were used in these reactions as listed below. GAPDH was used as the 
house keeping gene and relative levels of expression of the target genes were determined 
to GAPDH expression. 
Table 1. Primers used in the real-time PCR study. 
2.15 Statistical analysis 
Unless stated otherwise, all values are presented as the mean ± S.D. Data analyses were 
performed using the Student’s t test. A p value of less than 0.05 was considered to 
indicate statistical significance which is indicated in the text. 
3. Results 
3.1 TG2 expression and activity is more elevated in IB3 cells than in C38 cells 
We first ascertained the level of TG2 expressed in the CF cell, IB3 and its corrected 
“add-back” cell, C38, using  western blot analysis (Figure 1A). The results show high 
levels of TG2 expressed in IB3 cells compared to C38 cells in whole cell lysates (Figure 
1A) and on the cell surface (Figure 1A) agreeing with  the work by Maiuri and 
colleagues [21], where high levels of TG2 were found in IB3 cells in vitro. The 
expression levels of TG2 were correlated with activity in whole cell lysates (Figure 1B) 
and with that measured at the cell surface (Figure 1C). IB3 cells showed high TG2 
Primers Forward Reverse 
TGFβ1 
GAPDH 
5’-tgcggcagtggttgagccgt-3’ 
5’-tgcaccaccaacttgcttagc-3’ 
5’-acctcggcggccggtagtga-3’ 
5’-ggcatggactgtggtcatgag-3’ 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
11 
 
activity compared to C38 cells both in cell lysates and at the cell surface which could be 
significantly inhibited using the TG2 inhibitor, R283 (Figure 1B). Use of R283 and other 
TG2 inhibitors, R292 and R294 (Figure 1C) also led to inhibition of cell surface 
TG2activity. The cell lysate and cell surface activity of TG2 on C38 was shown to be 
significantly lower than that found in CF IB3 cells (Figure 1B and C).  
3.2 EMT markers are more elevated in IB3 cells than in C38 cells 
Epithelial-Mesenchymal transition (EMT) is characterized by the loss of the epithelial 
cell phenotype such as tight and adhesion junction proteins and the acquisition of a 
mesenchymal phenotype. TGFβ1 has been shown to play a key role in EMT in the lungs, 
kidney and pancreas [22] and this function involves nuclear restructuring via 
transcriptional repressors e.g. Snail, Slug and Twist. In order to show if this phenomenon 
was occurring in the high TG2 expressing IB3 cells, FN, N-cadherin and Slug expression 
was measured in both IB3 and C38 cells (Figure 1D). Results show increased expression 
of FN, N-cadherin and the transcription repressor Slug in IB3 cells compared to the C38 
cells (Figure 1D). As a result of this mesenchymal transition, IB3 cells show an 
increased migratory phenotype, compared to the C38 cells (Figure 1E and F). Inhibition 
of TG2 activity in IB3 cells showed a significant inhibition of cell migration, while there 
was no significant effect found in the C38 cells treated with R283 (Figure 1E and F).   
3.3 Modulation of TG2 activity regulates EMT progression 
To determine the effect of TG2 knock down on EMT progression the differences in the 
expression of EMT markers FN, N Cadherin and Slug in IB3 cells was measured after 
their transfection with a Lentiviral vector containing TG2 shRNA. Cells were cultured for 
48h and whole cell lysates analysed for EMT markers by western blotting (Figure 2A). 
Reduced expression of TG2 in IB3 cells correlated with a reduction in the expression of 
the EMT markers.         
3.4 Induction of EMT in primary human bronchial epithelial cells-role of TG2   
We next examined the effect of increasing TG2 expression in human primary bronchial 
epithelial cells (HBECs). Expression of TG2 was increased in these cells by transduction 
with Lentiviral particles carrying TG2 (Figure 2B).  An increase in TG2 expression in 
these cells resulted in an increase in expression of EMT markers FN, N-Cadherin, Slug, 
and a decrease of the epithelial marker E-Cadherin (Figure 2B). When HBEC cells were 
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treated with TGFβ1, as found with the virally transduced cells showing increased TG2 
expression, there was an increase in TG2 expression accompanied by an increase in the 
EMT markers FN, N-Cadherin and a decrease of the epithelial marker E-Cadherin 
(Figure 2C). These EMT markers could be reduced when cells were treated with 
TGFβ1in the presence of the TG2 inhibitor R283.  
3.5 TGFβ1 activity is blocked by TG2 inhibition 
Our results so far link TG2 to TGFβ1-induced EMT. Our hypothesis was that TGFβ1, 
through its activation by TG2, is the driver of EMT progression in CF airway bronchial 
epithelial cells. Therefore in this section we looked at the expression and levels of TGFβ1 
in CF IB3 cells and C38 cells.  
Both CF IB3 and control C38 cells express TGFβ receptors (TGFβR) I and II (Figure 
3A) but a significantly higher TGFβ1 gene expression was found in IB3 cells compared 
to C38 cells (Figure 3B). Measurement of total TGFβ1 levels in IB3 and C38 cells 
indicated TGFβ1 to be significantly higher in IB3 cells compared to C38 cells which 
could be reduced by TG2 inhibitors R283, R292 and R294 (Figure 3C). The cell 
permeable TG2 inhibitors R283 and the less cell permeable TG2 inhibitors R292 and 
R294 all inhibited TGFβ1 levels present in the cell culture medium at comparable levels, 
suggesting that the cell surface TG2 activity is the important factor in the activation of 
TGFβ1. 
We next looked to see if an up regulation of TG2 following treatment with TGFβ1 
correlated with an increase in α-SMA in C38 cells. Our results shown in  Figure 3D 
indicate  that in the presence of TGFβ1, C38 cells re-oriented their structural morphology 
to assume a fibrous spindle shape with an increase in expression of TG2 and the 
myofibroblast marker, α-SMA (Figure 3E and 3F). This increase in TG2 expression is 
accompanied by an increase in FN (Figure 3F), and N-cadherin (Figure 3G) when C38 
cells are stimulated with TGFβ1. When TG2 activity is reduced by the highly TG2 
specific inhibitors 1-33 and 1-155 and the TG2 inhibitor R283 (Figures 3F and G), the 
TG2 profile and EMT profile start to reverse back to that found in C38 cells prior to 
TGFβ1 stimulation. Loss of the EMT markers following TG2 inhibition is accompanied 
by a reduction in Smad signalling both in C38 cells after treatment with TGFβ1 and in 
IB3 cells without TGFβ1 treatment (Figure 3H). This mimics the effects of TG2 
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expression in IB3 cells and in primary bronchial epithelial cells whereby TGFβ1 
increases the expression of TG2 and TG2 in turn increases TGFβ1 levels leading to the 
progression of EMT (Figure 2D). We next looked at the effect of the TGFβ receptor 
inhibitor SB 431542 on EMT in IB3 cells both in isolation and in combination with the 
cell impermeable inhibitor R292 in order to further confirm that TGFβ1 is driving EMT 
and that TG2 is working via a TGFβ mechanism. Figure 3I shows that both the TGFβ 
receptor inhibitor SB 431542 [23] and R292 lead to comparable changes in the 
expression of TG2` and in the EMT markers FN, N-cadherin and Slug which were not 
substantially different overall to the changes found when the two inhibitors were 
combined. Moreover, Figure 3J demonstrates how when C38 cells are cultured in the 
presence of rhTGFβ1 protein, they assume a fibroblast-phenotype with a consequent loss 
in epithelial like cell morphology, paralleling the increase in FN deposition and 
expression of other EMT markers (Figure 3F and G), which can in part be reversed in 
the presence of the TG2 inhibitor R283.  
The finding that TG2 inhibition can reduce the effect of exogenously added TGFβ1 also 
suggests its activity may be important in TGFβ1 signalling in addition to its role in 
TGFβ1 activation. Recent reports have indicated that TGFβ1 can be crosslinked into a 
collagen matrix by transglutaminase leading to its enhanced and prolonged signalling 
[10]. We therefore looked for the presence of TGFβ1 in the matrix of CF IB3 cells. 
Figure 3K shows that the matrix of IB3 cells does contain TGFβ1 in a monomeric form. 
Inhibition of TG2 activity using its specific inhibitors R283 and 1-155 was able to reduce 
the TGFβ1 monomer to around 50% of control. As the control treatment, the addition of 
active TG2 (1µg/ml) induced the formation of TGFβ1 polymer in the ECM (Figure 3K), 
further suggesting that TGFβ1 can act as a substrate for TG2 and that TG2 crosslinking 
activity is involved in the ECM deposition of TGFβ1. 
3.6 The role of TG2 in ALI conditions 
To confirm the results observed in submerged culture in a more physiological culture 
setting, IB3 and C38 cells were grown under an Air Liquid Interface (ALI) format. In IB3 
cells, the protein expression of TG2 and EMT markers FN and N-Cadherin is more 
elevated than in C38 cells (Figure 4A and B) which  agrees with the data for these cells 
observed in submerged culture (Figures 1 and 2). When IB3 cells are transfected with a 
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TG2 shRNA, the protein expression of TG2 and EMT markers decrease (Figure 4C), this 
is in agreement with results previously observed in submerged culture (Figures 2A). 
Moreover, when cells are incubated with the TGFβ receptor inhibitor SB 431542 or 
R292, either in isolation or combined, EMT markers and TG2 expression decrease in a 
similar manner to that found in submerged culture further, confirming that TG2 is acting 
via a TGFβ mechanism (Figure 4D). In addition, when TG2 is knocked down using this 
TG2 targeted shRNA and cultured under ALI conditions the value of TEER significantly 
increases (Figure 4E). 
When primary HBEC cells are transduced with TG2 containing Lentiviral particles and 
grown under ALI conditions the EMT marker levels increase in these cells (Figure 4F), 
which is in accordance with the results observed in submerged culture (Figure 2C). The 
TEER (Figure 4G) also significantly decreases when cells were transduced with TG2. 
This suggests, in keeping with the observed increase in EMT markers, that there is a loss 
in epithelial cell like morphology resulting in a loss in tight junctions with a 
corresponding increase in FN deposition. 
3.7 Inhibition of TG2 and EMT lead to an increase in the maturation of mutant 
CFTR in IB3 cells 
IB3 cells were treated during a 48h culture without or with a bank of different TG2 
inhibitors. This time frame was chosen since we found it reduces the expression of TG2 
with a parallel reduction in EMT markers. The level of the CFTR C band in the 
membrane fraction of the treated cells was then determined by Western Blotting (Figure 
5). When cells are treated with Cysteamine, an increase of CFTR C-Band in the 
membrane fraction can be observed (Figure 5A and B). This result is in accordance with 
the paper by Maiuri et al [1]. Cysteamine is not a specific TG inhibitor, but 2-18 and 1-
155 are highly specific for TG2 [24]. When these two TG2 specific inhibitors were used, 
an increase of CFTR C-band in the membrane fraction of IB3 cells can be observed 
(Figure 5A, B and C). When a combination of Cysteamine and 1-155 is used, a higher 
increase can be observed (Figure 5B). Importantly, inhibition of TG2 activity by its 
specific inhibitor 1-155 restored CFTR at the plasma membrane by around 80%, and was 
more  efficient that Cysteamine in this function in keeping with the potency of the two 
inhibitors for TG2  (Figure 5D).  
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4. Discussion 
CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) [25]. The most common mutation is F508del, resulting in multiple organ 
damage amongst which lung destruction ranks first as the major cause of morbidity. The 
importance of TG2 in CF has been well reported, and cysteamine, a pan transglutaminase 
inhibitor which may have other inhibitory effects has been tested in a Phase 2 clinical 
trial for CF with positive outcomes [7]. A series of recent reports [1, 25] have 
demonstrated the intracellular involvement of TG2 in CF epithelia. It was reported that 
activation of TG2 in CF bronchial epithelial cells by stress related increases in 
intracellular Ca
2+
 lead to protein crosslinking, culminating in blocked autophagy and 
protein aggregate accumulation [25].  
In this report, we have looked at another well-established role of TG2  related to its 
extracellular protein crosslinking using the well characterised CF IB3 cells and its  
control cells C38 (with transfected add back truncated functional CFTR). IB3 cells, like 
other reported CF epithelial cells tested [25], express higher levels of TG2 and higher 
levels of  transamidase activity compared to their control cells such as C38 cells or 
primary human bronchial epithelial cells. This increase in TG2 expression was reported 
to be result of the sumoylation of TG2 resulting in its increased longevity within the cell 
[26]. Importantly and in keeping with the extracellular crosslinking role of TG2 an 
increased presence of the enzyme is found on the cell surface of IB3 cells. These cells 
were therefore used as the major cell model in our subsequent work together with 
primary bronchial epithelial cells which were used to verify our findings in these 
epithelial cell lines.  
Increases in extracellular TG2 are now well established to play an important role in 
fibrosis where matrix crosslinking and activation of matrix bound TGFβ1 by TG2 
contribute to fibrosis progression. This is particularly important since uncontrolled 
airway remodelling occurs in CF patients which is now recognized to start early in life 
and is linked to a poor pulmonary outcome with extensive fibrosis [27]. A similar 
process in CF patients also known to start in babyhood is the destruction of the 
pancreas which is driven by fibrosis and noted when the disease was first recognized. 
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This is clinically important because nearly all pancreatic insufficient CF patients develop 
diabetes mellitus that is disproportionately lethal to females with CF [28]. 
An important growth factor unequivocally linked to both TG2 and fibrosis is TGFβ 
which is a family of 3 members, TGFβ1-3. Working via interaction with its receptors, 
TGFβ1  is  one  of  the  key  growth  factors  involved  in  fibrosis,  including  CF,  with  
increased levels reported in CF lungs [11]. In addition to its pro-inflammatory properties 
TGFβ1 has been shown recently to inhibit the biosynthesis of CFTR and also prevent 
the bio-functional rescue of CFTR [29]. Importantly over-expression of TGFβ1 in the CF 
lung has been associated with a more severe CF phenotype and TGFβ1 is reported to be 
increased in the plasma of children with CF [30]. One major role of TGFβ1 in addition to 
its many other fibrotic roles is its ability to induce the mesenchymal phenotype in cells, 
such as epithelial cells. This process termed EMT  is reported to be involved in number 
of different diseases: in cancer, EMT leads to the invasive phenotype in cancer cells; and 
during fibrosis EMT and other reported mesenchymal cell changes results in the 
deposition of a fibrotic matrix  in organs such as lungs and kidneys [31].  
Abnormal regulation of TG2 in a number of different cancer cells has been correlated 
with an increase in the expression of EMT markers [32-34]. The highlight of this process 
is the acquisition of a mesenchymal phenotype with an elevation in expression of EMT 
markers including FN, N-cadherin and the transcriptional marker, Slug, which facilitates 
invasive growth. 
Given this reported link between TG2, TGFβ1 and EMT the first part of our work was 
aimed at studying the potential involvement of TG2/TGFβ1-related EMT in CF cells and 
in primary human bronchial epithelial cells.   
We  demonstrate that  when TG2 activity is inhibited in IB3 cells either with TG2 
inhibitors or specific knock down of TG2 expression this leads to a significant reduction 
in FN, N-cadherin, Slug and TGFβ1 expression and in TGFβ1 levels leading to a  
reversal of  EMT. 
Similarly, when TG2 is overexpressed in primary HBEC cells, an increase in expression 
of EMT markers can be observed at both gene and protein level. This strongly suggests 
that an up regulation of TG2 expression and activity can drive EMT in CF IB3 cells and 
in primary bronchial epithelial cells where it is not normally expressed, revealing  for the 
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can also be first time the direct link between TG2 and EMT expression in  CF bronchial 
epithelia. Importantly, the finding that expression of both EMT markers and TG2 in IB3 
cells both in submerged an ALI culture can be reduced by the TGFβ receptor inhibitor SB 
431542 [23] and the cell impermeable TG2 inhibitor R292 in a comparable manner 
strongly suggest  that TG2 is working via a TGFβ1 mechanism. This link between TG2 
and TGFβ1 is in keeping with the work of Park et al [35] which showed that in A549 
lung cancer cells, TG2 induced EMT via TGFβ1 with an elevation of N-cadherin 
expression in these cells [35]. 
Importantly, to further prove our hypothesis, we show that inhibition of TG2 using both 
cell permeable and non-cell permeable TG2 inhibitors lowers the level of the TGFβ1 
protein which is keeping with the extracellular activation of matrix linked TGFβ1 by TG2 
[36-38]. Interestingly we also show that TG2 inhibition leads to a reduction in TGFβ1 
induced Smad signalling in C38 cells after addition of exogenous TGFβ1, leading to a 
reversal in EMT and a reduction in the expression of TG2. This is in agreement with 
results from Ritter and Davies [39] where it was shown that TG2 gene expression is 
regulated by TGFβ1 via a TGFβ1 Response Element (TRE) on the promoter site of the 
TG2 gene. However these data also suggest that TG2 may have another regulatory role in 
TGFβ1 function related to its signalling. In keeping with the results of Niger et al [10] 
who showed that transglutaminase mediated crosslinking of TGFβ1 into collagen led to 
its prolonged signalling [10], we found the presence of TGFβ1 in the matrix of CF IB3 
cells. Moreover in parallel with the loss of TGFβ1 induced Smad signalling in IB3 cells 
after TG2 inhibition there was a corresponding loss in matrix associated TGFβ1. Further 
evidence that TG2 is responsible for this crosslinking was shown by the finding that 
addition of exogenous TG2 to the IB3 cells led to polymerisation of the matrix TGFβ1 
present. Although we cannot rule out other mechanisms for how TG2 is acting in TGFβ1 
signalling, our data so far suggests that its crosslinking into the cell matrix may be one of 
them [35, 36, 38, 39]. 
Our data also indicate that this relationship between TG2 and TGFβ1 has the potential to 
lead to increases in matrix protein expression and deposition ultimately leading to the 
fibrosis found in the lungs and other tissues of people with CF which starts at a very early 
age. Although other studies have attempted to relate EMT in alveoli cells to an aberration 
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of TGFβ1 [40], this study has provided the interrelationship between TG2, TGFβ1 and 
EMT in a bronchial epithelial model of CF and for the first time show that a fibrosis-
related response can be mediated via a TG2-TGFβ1-EMT driven pathway. 
Importantly we can demonstrate this relationship both in CF cells grown in submerged 
culture and also in more physiologically related condition using ALI where we 
demonstrate that the presence of EMT in IB3 cells and the induction of EMT in primary 
bronchial epithelial cells leads to a reduction in TEER levels, which in the lung would 
implicate a reduction of tight junctions in the epithelial barrier. Interestingly EMT has 
also been shown to occur in chronic obstructive pulmonary disease [41], where patients 
have many comparable clinical symptoms to that of CF sufferers. 
The use of CFTR potentiators and correctors has been deemed as the recent breakthrough 
in CF therapy [6, 42], but these have had limited success when tested in patients carrying 
the F508del CFTR mutation. Moreover, given reports that increased TGFβ1 levels found 
in CF patients can lead to lowered expression of CFTR, inhibit its translocation to the cell 
membrane, and in addition, block the functional correction of CFTR, we next turned our 
attention to looking at the effects of specifically targeted TG2 inhibitors on CFTR 
processing. Luciani et al [25] observed in CFBE41o- cells transfected with F508del 
CFTR that the non-selective TG inhibitor cysteamine reduced CFTR recycling and 
sustained the channel at the apical membrane compared to CFTR correctors, VX-325 or 
Corr-4a.  
In this study we used a bank of TG2 inhibitors, including the cell permeable and highly 
potent TG2 selective peptidomimetic inhibitor 1-155, a further  potent cell impermeable 
peptidomimetic TG2 specific inhibitor 2-18 and the cell impermeable peptidic inhibitor 
R281 plus cysteamine which was used as the internal positive control [16]. Our recent 
work demonstrated the high specificity and potency of these peptidomimetic inhibitors, 
which showed no toxicity when used in experimental animals [16]. All TG2 inhibitors 
were incubated with IB3 cells for 48h prior to testing since we demonstrated this time 
period lowered both TGFβ1 levels and TG2 expression (Figure 3C and 3H). Following 
TG2 inhibition we observed that CFTR translocation to the cell membrane, an indicator 
of the improvement of CFTR maturity, significantly increased, in particular when cells 
were pre-incubated with the highly potent and TG2 selective  inhibitor 1-155. 
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Interestingly the amount of CFTR found at the cell membrane could be enhanced even 
further when combined with the pan TG inhibitor cysteamine.  
Our findings are therefore in keeping with those of Luciani et al [25] with respect to the 
improved translocation of the ΔF508 CFTR found when CF bronchial epithelial cells are 
incubated with pan TG inhibitors such as cysteamine or R283. This group demonstrated 
that these pan transglutaminase inhibitors stabilize and increase NBD-1:ICL interactions 
allowing  the read through of ΔF508 CFTR copies whilst precluding their proteosomal 
degradation, hence, increasing the number of stable and mature CFTR copies that are 
trafficked to the plasma membrane. Hence we cannot rule out that our TG2 selective 
inhibitors are also in addition to their effects on EMT and TGFβ levels are working in 
part by their effects on preventing proteosomal degradation of the mutated CFTR. 
Importantly in this report unlike the work reported by Luciani et al [23], we use for the 
first time highly potent and TG2 selective inhibitors and confirm the importance of TG2 
activity in the regulation of CFTR stability and processing. Hence in future work it would 
be interesting to test if these TG2 selective inhibitors can improve CFTR stability and 
processing in homozygous ΔF508 CFTR mouse models, particularly in the nasal 
epithelium where CFTR is well expressed in these mice. Unlike human CF suffers as far 
as we are aware there have been no reports [43] to indicate that these F508del CFTR 
mice have elevated levels of TGFβ in their lungs or that extensive remodeling and 
fibrosis occurs in the lung early in life as it does in humans. Hence any major effects of 
selective TG2 inhibition on these mice with respect to CFTR stability and processing if 
performed on young mice might be attributed to their effects on precluding proteosomal 
degradation of the F508del CFTR. 
In summary we show that TG2 has an additional pathological role in CF related to its 
importance in TGFβ1 activation and signalling which sustains TG2 levels, interferes with 
CFTR expression and processing and in addition together with increased TG2 levels, 
promotes increased matrix deposition leading to fibrosis in CF patients.  
5. Conclusion 
This paper demonstrates that TG2 has other pathological roles in CF in addition to those 
reported in the literature. It demonstrates that TG2 is one of the major drivers in CF 
pathology, in particular in fibrosis progression via its ability to regulate TGFβ1 activation 
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and signalling leading to the induction of epithelial-mesenchymal transition (EMT) in CF 
epithelia. We demonstrate that induction of EMT in CF cells affects the epithelial barrier 
by impairing  tight junctions as demonstrated by a reduction in TEER values, induces 
matrix deposition, increases cell mobility and affects CFTR stability and maturity. 
Inhibition of TG2 activity using either TG2-specific inhibitors or knock down of TG2 
expression is able to counteract the effect of TGFβ1 and in turn reverse EMT, reduce 
levels of active TGFβ1 produced by CF epithelial cells and as a consequence help prevent 
fibrosis progression. Importantly TG2 specific inhibitors are able to help restore the 
function and maturity of CFTR in CF cells. This work reveals for the first time the 
potential of using TG2-specific non-toxic inhibitors as therapeutic agents in the treatment 
of CF.    
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9. Figure legends 
Figure 1. TG2 expression and activity in C38 and in IB3 cells. (A) Western blotting 
was performed to detect the TG2 expression in a whole lysate of IB3 and C38 cells, as 
well as cell surface (CS) TG2 following biotinlyation of cell surface proteins. A 
representative images from 3 separate experiments with the densitometry ratios show 
below after normalisation of protein loading with GAPDH. (B) TG2 activity in both IB3 
and C38 cells was measured via biotin-cadaverine incorporation assay, while TG2 
inhibitor R283 was used. *, p<0.05. (C) Cell surface TG2 activity in the of IB3 and C38 
cells was performed as introduced in the Experimental Procedures. R283, R292 and R294 
are TG2 inhibitors. n=3. *, p<0.05. (D) EMT marker screening in IB3 and C38 cells.  
Repesentative images showing FN, N-Cadherin and Slug proteins in IB3 and C38 cells 
detected by Western Blot. The densitometry ratio of the different bands is show below 
taken from 3 separate experiments. (E) and (F) Cell migration assay. Representative 
migration images of IB3 and C38 cells is shown over 12h (E) with or without R283 
treatment and analyzed and plotted as the % relative wound density against time using an 
ESSEN IncuCyte system (F) as described in the Experimental Procedures.  
Figure 2. (A) Inhibition of TG2 via shRNA or inhibitor R283 treatment blocks EMT in 
IB3 cells. EMT Proteins (E-Cadherin, N-Cadherin, FN, Slug) in IB3 cells when TG2 is 
inhibited by TG2 shRNA detected via Western blotting. (B) Induction of EMT in HBEC 
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cells via over-expressing TG2. TG2 was over-expressed using Lentiviral particles in 
HBEC cells, while the virus containing the empty vector was used as the control 
treatment as introduced in the Experimental Procedures. Mesenchymal and epithelial 
markers were measured via Western blotting. (C) Inhibition of TG2 activity via R283 
treatment blocks the effect of TGFβ1-induced EMT. HBEC cells were treated with 
3ng/ml rhTGFβ1 for 48h in the presence or absence of R283. GAPDH was used as the 
equal loading standard.      
Figure 3. Effect of TG2 on TGFβ1-induced EMT. (A) The presence of TGFβ receptor 
I (RI) and II (RII) in IB3 and C38 cells were detected via Western blotting. (B) TGFβ1 
expression in IB3 and C38 cells determined by RT-PCR as described in Experimental 
Procedures. Expression level of TGFβ1 were normalized to GAPDH expression. *, 
p<0.05. (C) TGFβ1 levels in IB3 and C38 cells. ELISA was performed following 
manufacture’s instructions to detect the presence of TGFβ1. *, p<0.05. (D) Morphology 
changes of C38 cells induced by TGFβ1. Representative images of C38 cells treated with 
or without 3ng/ml TGFβ1 for 48h and the images were taken using a Nikon digital 
camera. (E) Immunofluorescence staining was performed to detect the presence of αSMA 
in C38 cells treated with or without TGFβ1 as introduced in Experimental Procedures. 
(F-H) C38 cells were treated with 3ng/ml TGFβ1 for 48h in the presence of various TG2 
inhibitors, including R283, 1-33, 1-155 and R294. Western blotting was carried out to 
detect the presence of TG2, mesenchymal markers FN and N-cadherin and active 
phosphorylated (p) Smad2/3. GAPDH or total (t) Smad2/3 were used to ensure the equal 
loading and normalization of p-Smad2/3, respectively. (I) Effect of non-cell permeable 
TG2 inhibitor R292 and TGFβ receptor inhibitor SB 431542 on EMT in IB3 cells. IB3 
cells were treated with R292 (250µM) and TGFβ receptor inhibitor SB 431542 (10µM) 
either alone or in combination for 48h. The presence of TG2, FN, N-cadherin and Slug in 
the cell lysates was detected via Western blotting. GAPDH was used to ensure equal 
loading. (J) Morphology of C38 cells treated with TGFβ1 in the presence or absence of 
R283. Representative images from C38 cells treated with 3ng/ml TGFβ1 with or without 
R283 as in introduced in (F) at 10x and 20x magnification taken using a Nikon digital 
camera. (K) Presence of TGFβ in the ECM. IB3 cells were treated with or without R283 
(500µM) or 1-155 (1µM), or with the addition of 1µg/ml rhTG2 for 48h. The remaining 
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ECM was collected after lifting the cells with 2mM EDTA in PBS, pH 7.4, and used to 
detect the presence of TGFβ1 or FN via Western blotting.  
Figure 4. ALI condition and TEER measurement. (A) TG2 and EMT Proteins 
expression in IB3 and C38 cells cultured at ALI. (B) Visualization by immunostaining of 
TG2 and EMT marker FN in IB3 and C38 cells cultured at ALI. (C) TG2 and EMT 
proteins expression in IB3 cells cultured at ALI when cells are transfected with TG2 
shRNA. VC, vector control. (D) Presence of EMT markers in ALI in IB3 cells. IB3 cells 
treated with R292 (250 µM) or TGFβ receptor inhibitor SB 431542 (10µM)  alone or in 
combination in the ALI culture was used to detect expression of the EMT markers FN, N-
cadherin and Slug, as well as TG2, via Western blotting. GAPDH was used to ensure the 
equal loading. (E) The TEER values in IB3 cells cultured at ALI when cells are 
transfected with TG2 shRNA. *, p<0.05. VC, vector control. (F) TG2 and EMT Proteins 
expression in HBEC cells cultured at ALI when cells are transfected with TG2. (G) 
TEER Measurement in HBEC cultured at ALI without or with TG2 transfection. *, 
p<0.05.  
Figure 5. Restoration of CFTR functions by TG2 inhibition in IB3 cells. The 
presence of CFTR C-band in IB3 cells were labelled via biotinlyation and detected via 
Western blotting. (A) CFTR C-Band when IB3 cells are treated with Cysteamin (250µM) 
or 1-155 (1µM). (B) CFTR C-Band when IB3 cells are treated with Cysteamine, 
(250µM) with 1-155 (1µM) or Cysteamine and 1-155. (C) CFTR C-Band (Membrane 
Fraction) and TG2 (Total Extract) when IB3 cells are treated with Cysteamine (250µM) 
or TG2 specific inhibitors 2-18 (50µM), R281 (250µM) and 1-155 (at concentrations 
shown). (A), (B) and (C) show representative images from 3 separate experiments with 
the densitometry ratios show below after normalisation of protein loading with GAPDH. 
(D) The mean values ± S.D. taken from the 3 separate experiments using cysteamine at 
250µM or 1-155 at 1µM as the inhibitor treatment with the DMSO control normalised to 
100%. *, p<0.05. 
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Graphical Abstract 
 
 Highlights  
 Increased TG2 expression in CF epithelia increases TGFβ1 levels.  
 Increased TGFβ1 and TG2 leads to Epithelial Mesenchymal Transition (EMT).  
 EMT leads to poor CFTR stability and increased matrix deposition  
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 Inhibition of TG2 helps restore CFTR stability and leads to reversal of EMT.  
